Cyclolauranes as plausible chemical scaffold against Naegleria fowleri - 20/04/22
, Jacob Lorenzo-Morales a, b, c, f, ⁎
, Ana R. Díaz-Marrero d, e, ⁎
, José J. Fernández d, g, ⁎ 
Abstract |
Primary amoebic meningoencephalitis (PAM) is a central nervous system (CNS) disease caused by Naegleria fowleri that mainly affects children and young adults with fatal consequences in most of the cases. Treatment protocols are based on the combination of different antimicrobial agents, nonetheless there is the need to develop new anti-Naegleria compounds with low toxicity and full effects compared to the currently used drug combination. The marine environment is a well-established source of bioactive natural products. In this work, we have focused on the structure of Laurencia cyclolaurane-type sesquiterpenes as potential chemical model against Naegleria species. The effects of debromolaurinterol (1) to induce PCD/apoptosis-like events in Naegleria fowleri have been evaluated, revealing that this compound induced reduction of ATP production showing a decrease of 99.98% in treated parasite cells. A SAR analysis have been supported with molecular modeling and analysis of the in silico ADME/Tox properties of the Laurencia sesquiterpenes debromolaurinterol (1), laurinterol (2) and allolaurinterol (3), which reinforce cyclolaurane metabolites as plausible molecular models to develop PAM treatments.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Cyclolaurane-type sesquiterpenes evaluated as chemical models against Naegleria. |
• | Mechanisms of PCD/apoptosis-like events in Naegleria fowleri are analyzed. |
• | Debromolaurinterol is the most efficient compound with an ATP inhibition of 99,98%. |
• | In silico ADME/Tox analysis revealed good CNS activity. |
Keywords : Debromolaurinterol, Laurinterol, Naegleria fowleri, Cyclolaurane, Primary amoebic meningoencephalitis, ATPase
Plan
Vol 149
Article 112816- mai 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
